Literature DB >> 29106524

Cardiac myocyte β3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling.

Nerea Hermida1, Lauriane Michel1, Hrag Esfahani1, Emilie Dubois-Deruy1, Joanna Hammond1, Caroline Bouzin1, Andreas Markl1, Henri Colin1, Anne Van Steenbergen2, Christophe De Meester2, Christophe Beauloye2, Sandrine Horman2, Xiaoke Yin3, Manuel Mayr3, Jean-Luc Balligand1.   

Abstract

Aims: Human and mouse cardiac beta3-adrenergic receptors (beta3AR) exert antipathetic effects to those of beta1-2AR stimulation. We examined their role in modulating myocardial remodelling, particularly fibrosis in response to haemodynamic stress. Methods and results: Mice with cardiac myocyte-specific expression of beta3AR (ADRB3-tg) or tamoxifen-inducible homozygous deletion (c-Adrb3-ko, with loxP-targeted Adrb3) were submitted to transaortic constriction. A superfusion assay was used for proteomic analysis of paracrine mediators between beta3AR-expressing cardiac myocytes and cardiac fibroblasts cultured separately. We show that cardiac beta3AR attenuate myocardial fibrosis in response to haemodynamic stress. Interstitial fibrosis and collagen content were reduced in ADRB3-tg, but augmented in c-Adrb3-ko. ADRB3 and collagen (COL1A1) expression were also inversely related in ventricular biopsies of patients with valve disease. Incubation of cardiac fibroblasts with media conditioned by hypertrophic myocytes induced fibroblast proliferation, myo-differentiation, and collagen production. These effects were abrogated upon ADRB3 expression in myocytes. Comparative shotgun proteomic analysis of the myocyte secretomes revealed a number of factors differentially regulated by beta3AR, among which connective tissue growth factor [CTGF (CCN2)] was prominently reduced. CTGF was similarly reduced in stressed hearts from ADRB3-tg, but increased in hearts from c-Adrb3-ko mice. CTGF expression was mediated by reactive oxygen species production which was reduced by ADRB3 expression in vitro and in vivo. This antioxidant and anti-fibrotic effect involved beta3AR coupling to the neuronal isoform of nitric oxide synthase (nNOS) in cardiac myocytes, as both were abrogated upon nNOS inhibition or Nos1 homozygous deletion.
Conclusion: Cardiac beta3AR protect from fibrosis in response to haemodynamic stress by modulating nitric oxide and oxidant stress-dependent paracrine signaling to fibroblasts. Specific agonism at beta3AR may offer a new therapeutic modality to prevent cardiac fibrosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29106524     DOI: 10.1093/eurheartj/ehx366

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  23 in total

Review 1.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

2.  Role of the β3-adrenergic receptor subtype in catecholamine-induced myocardial remodeling.

Authors:  Gizem Kayki Mutlu; Ebru Arioglu Inan; Irem Karaomerlioglu; V Melih Altan; Nilgun Yersal; Petek Korkusuz; Marcella Rocchetti; Antonio Zaza
Journal:  Mol Cell Biochem       Date:  2018-01-23       Impact factor: 3.396

Review 3.  Nitric oxide signalling in cardiovascular health and disease.

Authors:  Charlotte Farah; Lauriane Y M Michel; Jean-Luc Balligand
Journal:  Nat Rev Cardiol       Date:  2018-02-01       Impact factor: 32.419

4.  Leptin mediates postprandial increases in body temperature through hypothalamus-adrenal medulla-adipose tissue crosstalk.

Authors:  Rachel J Perry; Kun Lyu; Aviva Rabin-Court; Jianying Dong; Xiruo Li; Yunfan Yang; Hua Qing; Andrew Wang; Xiaoyong Yang; Gerald I Shulman
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

5.  Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism.

Authors:  Xin Zhang; Can Hu; Yu-Pei Yuan; Peng Song; Chun-Yan Kong; Hai-Ming Wu; Si-Chi Xu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Cell Biol Toxicol       Date:  2021-01-20       Impact factor: 6.691

Review 6.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

Review 7.  Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Jolanda van der Velden; Carlo G Tocchetti; Gilda Varricchi; Anna Bianco; Vasco Sequeira; Denise Hilfiker-Kleiner; Nazha Hamdani; Adelino F Leite-Moreira; Manuel Mayr; Ines Falcão-Pires; Thomas Thum; Dana K Dawson; Jean-Luc Balligand; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

8.  Upregulation of COX-2 and PGE2 Induced by TNF-α Mediated Through TNFR1/MitoROS/PKCα/P38 MAPK, JNK1/2/FoxO1 Cascade in Human Cardiac Fibroblasts.

Authors:  Chuen-Mao Yang; Chien-Chung Yang; Li-Der Hsiao; Chia-Ying Yu; Hui-Ching Tseng; Chih-Kai Hsu; Jiro Hasegawa Situmorang
Journal:  J Inflamm Res       Date:  2021-06-28

9.  Beta 3 adrenoreceptors protect from hypertrophic remodelling through AMP-activated protein kinase and autophagy.

Authors:  Emilie Dubois-Deruy; Roselle Gelinas; Christophe Beauloye; Hrag Esfahani; Lauriane Y M Michel; Chantal Dessy; Luc Bertrand; Jean-Luc Balligand
Journal:  ESC Heart Fail       Date:  2020-03-10

10.  Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).

Authors:  Anne-Catherine Pouleur; Stefan Anker; Dulce Brito; Oana Brosteanu; Dirk Hasenclever; Barbara Casadei; Frank Edelmann; Gerasimos Filippatos; Damien Gruson; Ignatios Ikonomidis; Renaud Lhommel; Masliza Mahmod; Stefan Neubauer; Alexandre Persu; Bernhard L Gerber; Stefan Piechnik; Burkert Pieske; Elisabeth Pieske-Kraigher; Fausto Pinto; Piotr Ponikowski; Michele Senni; Jean-Noël Trochu; Nancy Van Overstraeten; Rolf Wachter; Jean-Luc Balligand
Journal:  ESC Heart Fail       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.